PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33593794-8 2021 We investigated the impact of modulating ITK signaling with ibrutinib, an FDA-approved tyrosine kinase inhibitor, and found that anti-OX40/anti-CTLA-4/ibrutinib therapy further enhanced CD8+ T cell-specific Eomes expression, leading to enhanced tumor regression and improved survival, both of which were associated with increased T-cell effector function across multiple tumor models. ibrutinib 60-69 IL2 inducible T cell kinase Homo sapiens 41-44 33593794-8 2021 We investigated the impact of modulating ITK signaling with ibrutinib, an FDA-approved tyrosine kinase inhibitor, and found that anti-OX40/anti-CTLA-4/ibrutinib therapy further enhanced CD8+ T cell-specific Eomes expression, leading to enhanced tumor regression and improved survival, both of which were associated with increased T-cell effector function across multiple tumor models. ibrutinib 151-160 IL2 inducible T cell kinase Homo sapiens 41-44